sellWeak10b5-1 plan
Joan Nickerson sold $12k of VERV
Chief Administrative Officer at Verve Therapeutics, Inc.. 1,514 shares at an average of $8.24, traded Apr 2, 2024, filed Apr 3, 2024.
Warning score
0Value
$12k
1,514 shares
Holdings after
8,659
-15% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- 0Trade size$12k at market
- +5Share of holdings soldSold 15% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-24-041237, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 1, 2024 | MOption exercise Common Stock10b5-1 | +3,315 | - | - | 10,173 | Apr 3, 2024 |
| Apr 2, 2024 | SOpen-market sale Common Stock10b5-1 | -1,514 | $8.24 | $12k | 8,659 | Apr 3, 2024 |
| Apr 1, 2024 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -3,315 | $0.00 | $0 | 9,945 | Apr 3, 2024 |
Related signals
Other insiders at Verve Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Verve Therapeutics, Inc. | Andrew D. Ashe See Remarks | $11k 2,681 shares | -1% | |
| 7Weak | Verve Therapeutics, Inc. | Allison Dorval Chief Financial Officer | $14k 3,350 shares | -20% | |
| 11Weak | Verve Therapeutics, Inc. | Sekar Kathiresan Chief Executive Officer | $41k 9,822 shares | -3% | |
| 0Weak | Verve Therapeutics, Inc. | Troy Lister Chief Scientific Officer | $9,084 2,189 shares | -24% | |
| 0Weak | Verve Therapeutics, Inc. | Joan Nickerson Chief Administrative Officer | $12k 2,777 shares | -14% | |
| 0Weak | Verve Therapeutics, Inc. | Jason Politi Chief Technical Ops. Off. | $13k 3,235 shares | -19% | |
| 7Weak | VERVsell Verve Therapeutics, Inc. | Allison Dorval Chief Financial Officer | $3,130 555 shares | -9% | |
| 39Weak | VERVbuy Verve Therapeutics, Inc. | Andrew D. Ashe See Remarks | $476k 76,000 shares | +29% | |
| 48Moderate | VERVbuy Verve Therapeutics, Inc. | Krishna Yeshwant director, owner | $18M 1,800,000 shares | - | |
| 12Weak | VERVsell Verve Therapeutics, Inc. | Allison Dorval Chief Financial Officer | $6,343 554 shares | -12% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.